Product Name:
ILK1-pS343
Product Number:
ab-pk661
Target Full Name: Integrin-linked protein-serine kinase-1
Target Alias: 59 kDa serine/threonine protein kinase; ILK1; ILK-1; Integrin-linked kinase; Kinase ILK; P59ILK; ILK2; DKFZp686F1765; P59; CCDS7768.1; ENSG00000166333
Product Type Specific: ILK1 protein kinase phosphosite-specific antibody
Antibody Code: PK661
Antibody Target Type: Phosphosite-specific
Antibody Phosphosite: S343
Protein UniProt: Q13418
Protein SigNET: ILK1
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human ILK1 sequence peptide Cat. No.: PE-04AMU99
Antibody Immunogen Sequence: DVKF(pS)FQC
Antibody Immunogen Description: Corresponds to amino acid residues D339 to C346; in the protein kinase catalytic domain activation T loop region between subdomains VII and VIII. S343 phosphorylation stimulates phosphotransferase activity and interaction with Akt1. Phosphorylation regulates molecular association, including inducing interaction with Akt1. This is one of the minor in vivo phosphorylation sites in ILK1 (≥1 report from high throughput mass spectrometry studies recorded in PhosphoSitePlus).
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 0.15 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Potency: Medium immunoreactivity with immunogen peptide on dot blots.
Antibody Species Reactivity: This antibody detects the target phosphoprotein in the following species due to conservation of amino acid sequence: Human | Rhesus macaque | Dog | Rat | Frog | Zebra fish.
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 50-55 kDa.
Antibody Specificity: Very high
Antibody Cross Reactivity: No significant cross-reactive proteins detected in phenylarsine oxide (PAO)+vanadate-treated HeLa cells, EGF-treated A431 cells and insulin-treated MCF7 cells, when these cells were homogenized in SDS-PAGE sample buffer.
Related Product 1: ILK (339-346) pS343 antibody blocking peptide (Cat. No.: PE-04AMU99)
Related Product 2: ILK1-pY351 phosphosite-specific antibody (Cat. No.: AB-PK662)
Scientific Background: ILK (ILK1) is a protein-serine/threonine kinase of the TKL group and MLK family. It features an N-terminal domain with five ankyrin repeats (binding PINCH), a central Pleckstrin Homology (PH)-like domain (binding PtdIns(3,4,5)P3), and a C-terminal catalytic domain (binding beta-integrins, parvins, and paxillin). ILK is typically found in focal adhesions and the cytosol, but can also localize to centrosomes. It plays a critical role in the regulation of integrin-mediated signal transduction. It acts as a scaffold protein, linking integrins to the cytoskeleton, and is indispensable for the function of tissues like muscle, heart, and skin. ILK is a core component of the heterotrimeric ILK–PINCH–parvin (IPP) complex, which connects integrins to F-actin, facilitating cell adhesion, migration, and force generation. It is stimulated rapidly but transiently by both cell fibronectin interactions, as well as by insulin, in a PI3K-dependent manner, likely via the binding of PtdIns(3,4,5)P3. It is a component of the complex ILK-PINCH, which is thought to be a primary point for the convergence of integrin- and growth-factor signalling as well as a regulator of cell architecture, integrin-mediated adhesion, and anchorage-dependent cell growth in epithelial cells. Downstream targets of ILK include the beta-1 and beta-3 integrin subunits as well as Akt1 (at Ser-473) and GSK3b. The ILK mutation, H99D can modulate interactions with LIMS1. An E359K mutation can inactivate ILK. Mutations or dysfunction in the ILK gene are linked to cardiac diseases due to its role in maintaining muscle cell adhesion and architecture. ILK appears to be a oncoprotein (OP), but its relatively low rate of mutation in human cancers supports its assignment as a tumour requiring protein (TRP). It has been implicated as an oncoprotein due to its ability to activate Akt isoforms, although it has weak phosphotransferase activity that can be stimulated in vitro with manganese. Overexpression of ILK is correlated with promoting epithelial-mesenchymal transition (EMT), tumour metastasis, and invasion. This description may include information annotated by UniProt and/or Google AI.